Santen Pharmaceutical Full Year 2025 Earnings: EPS Beats Expectations

Santen Pharmaceutical (TSE:4536) Full Year 2025 Results

Key Financial Results

• Revenue: JP¥300.0b (flat on FY 2024).
• Net income: JP¥36.3b (up 36% from FY 2024).
• Profit margin: 12% (up from 8.8% in FY 2024).
• EPS: JP¥104 (up from JP¥72.59 in FY 2024).

We check all companies for important risks. See what we found for Santen Pharmaceutical in our free report.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Santen Pharmaceutical EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%.

Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Santen Pharmaceutical's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.